(Q37120208)

18 August 2017

1 reference

title

Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? (English)

1 reference

left ventricular hypertrophy

18 August 2017

main subject

arterial hypertension

0 references

1 reference

8

Giuseppe Mancia

1 reference

18 August 2017

1

Cesare Cuspidi

1 reference

18 August 2017

Arturo Esposito

2

1 reference

18 August 2017

Francesca Negri

3

1 reference

18 August 2017

Carla Sala

4

1 reference

18 August 2017

Meilikè Masaidi

5

1 reference

18 August 2017

Valentina Giudici

6

1 reference

18 August 2017

Alberto Zanchetti

7

1 reference

18 August 2017

publication date

6 March 2008

1 reference

Journal of Clinical Hypertension

18 August 2017

published in

1 reference

18 August 2017

volume

21

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

458-463

1 reference

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Left Ventricular Mass and Risk of Stroke in an Elderly Cohort

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Left ventricular mass change during treatment and outcome in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Prognostic significance of serial changes in left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Hydrochlorothiazide Is Superior to Isradipine for Reduction of Left Ventricular Mass: Results of a Multicenter Trial fn1fn1This study was supported by an unrestricted grant from Sandoz Pharmaceuticals, East Hanover, New Jersey.fn2fn2To discuss this a

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effects of losartan on hypertension and left ventricular mass: a long-term study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

A Comparison of the Effects of Mibefradil and Atenolol on Regression of Left Ventricular Hypertrophy in Hypertensive Patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Lack of autonomic contributions to tonic nitric oxide-mediated vasodilatation in unanesthetized free-moving rats

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

One-year study of felodipine or placebo for stage 1 isolated systolic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

β2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2007.85

7 January 2021

Identifiers

DOI

10.1038/AJH.2007.85

1 reference

18 August 2017

1 reference